Posted: 28 March 2023
Genetic Technologies Limited – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the initiation of phase 2 of the rollout plan for the geneType Multi-Test. The expanded panel now includes three new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine, all from the one simple saliva sample.
Each of the three new diseases that have been added to GeneType Multi-Test cause significant mortality and morbidity. According to the American Cancer Society there will be approximately 97,610 new cases of melanoma in 2023 and 7,990 people are expected to die from the disease. The Society’s estimates for pancreatic cancer are even more dramatic with 64,050 people newly diagnosed in 2023, with a staggering 50,550 people expected to die. In both cancers, identifying adults at increased risk of the disease gives patients and doctors the opportunity for additional surveillance which can enable earlier diagnosis and improve patient outcomes, extending life expectancy and saving lives. In the case of atrial fibrillation (AFib), the Centers for Disease Control (CDC) noted that in 2022 there were more than 454,000 hospitalizations and approximately 158,000 deaths each year in the United States due to AFib.
As with the other diseases included in Multi-Test, being able to stratify people at risk enables enhanced surveillance, early detection and early intervention which can lead to significantly improved patient outcomes. GTG’s CEO, Simon Morriss said, “The Company continues to deliver on our commitment to being a world leader in delivering personalised risk assessments to enable preventative healthcare for a range of serious diseases”.
